Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer
September 03 2019 - 9:00AM
InvestorsHub NewsWire
Feng Lin, MD, Ph.D.,
Joins Therapeutic Solutions International as Chief Scientific
Officer
Immuno-Oncology Nutraceutical
Company Positions Itself for Expansion into FDA
OCEANSIDE, CA --
September 3, 2019 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today the
recruitment of Feng Lin, MD, Ph.D.,
as Chief
Scientific Officer.
Dr. Lin has a stellar
track record of drug development in the area of immunology and
immuno-oncology having worked with the public company
Inovio
Pharmaceuticals,
where he developed technologies for gene delivery and therapeutic
DNA vaccines against cancer and infectious diseases in both R&D
and clinical settings. Subsequently, Dr. Lin served as Director of
Chinese Operations for MediStem
Inc,
which was acquired by the leading biotech company
Intrexon
(NYSE:
XON) on May 2014. It was the rapid clinical translation
model developed by Dr. Lin at Medistem that resulted in the
company's accelerated
FDA
clearance to begin clinical trials, which resulted in the sale of
the company.
"It is my honor to
work with the phenomenal
team
assembled
by Timothy Dixon, one of
the most innovative and creative CEOs that I have had the honor of
working with. Having watched Mr. Dixon develop
NanoStilbene™
from concept
to
patent
filing [1] to clinical
investigation [2]
to
commercialization [3],
I look forward to working with him and the
team
at
TSOI on increasing market
acceptance of this new approach to cancer immunotherapy"
said Dr. Feng
Lin.
Dr. Lin received his
postdoctoral training at the Sanford-Burnham Medical Research
Institute and his MD and Ph.D. at the Xiangya
Medical
School of Central South University, China. He has
authored over 20 peer-reviewed scientific publications, including
several in top journals such as Science, Cell, and Cancer Cell. He
holds several patents.
"Having interacted
numerous times with Dr. Lin, as well as recognizing the great
synergy between our approaches to science, medicine, and life, I am
looking forward to our working together to advance the deep and
broad pipeline that we have at Therapeutic Solutions
International" said Timothy Dixon,
President and CEO of the Company. "Given the previous
interactions between Dr. Lin and our Chief Medical Officer, Dr.
James Veltmeyer, I am sure that we will all synergize to not only
increase shareholder value but more importantly to help the many
patients suffering from cancer."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] https://www.google.com/patents/US9682047
[2] https://therapeuticsolutionsint.com/?page_id=745
[3] http://mynanostilbene.com
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024